A novel formulation of solubilised amphotericin B designed for ophthalmic use

International Journal of Pharmaceutics

Volumn 437, Issue 1-2, 2012, Pages 80-82

  Serrano, D R ^a   Ruiz Saldana H K ^a   Molero, G ^a   Ballesteros, M P ^a   Torrado, J J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Amphotericin B; Antifungal activity; Cyclodextrins; Eye drops; Stability

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; EYE DROPS; GAMMA CYCLODEXTRIN; THIOMERSAL;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; COMPLEX FORMATION; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; DRUG STERILITY; FUNGUS GROWTH; KERATOMYCOSIS; NONHUMAN; OSMOLARITY; PARTICLE SIZE; PH; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; GAMMA-CYCLODEXTRINS; OPHTHALMIC SOLUTIONS; SOLUBILITY;

EID: 84865526174     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.07.065     Document Type: Article

References (15)

1. R. Espada, S. Valdespina, C. Alfonso, G. Rivas, P. Ballesteros, and J.J. Torrado Effect of aggregation state on the toxicity of different amphotericin B preparations Int. J. Pharm. 361 2008 64 69
2. R. Espada, J.M. Josa, S. Valdespina, M.A. Dea, M.P. Ballesteros, J.M. Alunda, and J.J. Torrado HPLC assay for determination of amphotericin B in biological samples Biomed. Chromatogr. 22 2008 402 407
3. European Pharmacopoeia 6th ed. 2009 The Council of Europe pp. 5158-5160, Strasburg
4. Handbook of Pharmaceutical Excipients 6th ed. 2009 pp. 736-739
5. I.P. Kaur, C. Rana, and H. Singh Development of effective ocular preparations of antifungal agents J. Ocul. Pharmacol. Ther. 24 2008 481 493
6. P. Jansook, and T. Loftsson Cyclodextrins as solubilizers: effects of excipients and competing drug Int. J. Pharm. 379 2009 32 40
7. T. Loftsson, and E. Stefánsson Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye Acta Ophthalmol. Scand. 80 2002 144 150
8. T. Loftsson, and T. Järvinen Cyclodextrins in ophthalmic drug delivery Adv. Drug Deliv. Rev. 36 1999 59 79
9. K. Morand, A.C. Bartoletti, A. Bochot, G. Barratt, M.L. Brandely, and F. Chast Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability Int. J. Pharm. 344 2007 150 153
10. K.S. Rathore, and R.K. Nema An insight into ophthalmic drug delivery system Int. J. Pharm. Sci. Drug Res. 1 2009 1 5
11. J.A. Sánchez Brunete, M.A. Dea, S. Rama, F. Bolás, J.M. Alunda, S. Torrado, and J. Torrado Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis J. Drug Target. 12 2004 453 460
12. P.A. Thomas Fungal infections of the cornea Eye 17 2003 852 862
13. J.J. Torrado, R. Espada, M.P. Ballesteros, and S. Torrado Amphotericin B formulations and drug targeting J. Pharm. Sci. 97 2008 2405 2425
14. G.S. Tirucherai, and A.K. Mitra Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability and corneal permeation of acyl ester prodrugs of ganciclovir AAPS PharmSciTech 4 2003 (article 45)
15. C.G. Wilson, Y.P. Zhu, P. Kurmala, S. Roo, and D. Dhillon Opthalmic drug delivery Drug Delivery and Targeting 1st ed. 2001 pp. 298-319